- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Pharmacyclics Inc
+ Add to WatchlistPCYC:US
81.8600 USD 3.0300 3.57%As of 20:10:00 ET on 05/20/2013.
Snapshot for Pharmacyclics Inc (PCYC)
| Open: | 84.4200 | Day's Range: | 81.0550 - 85.8800 | Volume: | 842,302 |
|---|---|---|---|---|---|
| Previous Close: | 84.8900 | 52wk Range: | 28.7700 - 95.8500 | 1-Yr Rtn: | +161.70% |
Key Statistics for PCYC
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.3800 |
| Est. EPS (USD) (12/2013) | -0.5770 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 5,958.02 |
| Shares Outstanding (M) | 72.78 |
| 30 Day Average Volume | 720,631 |
| Price/Book (mrq) | 13.6297 |
| Price/Sale (ttm) | 66.3642 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for PCYC
Company Profile & Key Executives for PCYC
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs.
| Robert W Duggan "Bob"Chairman/CEO | Mahkam Zanganeh "Maky"Chief Operating Officer |
| Lori A KunkelChief Medical Officer | Maria FardisChief:Oncology Ops & Alliances |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
PCYC News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page